MitoQ 10 is a ubiquinone that accumulates within mitochondria driven by a conjugated lipophilic triphenylphosphonium cation (TPP + ). Once there MitoQ 10 is reduced to its active ubiquinol form and this has been used to prevent mitochondrial oxidative damage and to infer the involvement of reactive oxygen species in signalling pathways. Here we show MitoQ 10 is effectively reduced by complex II, but is a poor substrate for complex I, complex III and electrontransferring flavoprotein (ETF):quinone oxidoreductase (ETF-QOR). This differential reactivity could be explained if the bulky TPP + moiety sterically hindered access of the ubiquinone group to enzyme active sites with a long, narrow access channel. Using a combination of molecular modelling and an uncharged analog of MitoQ 10 with a sterically similar triphenylcarbon moiety (tritylQ 10 ), we infer that the interaction of MitoQ 10 with complex I and ETF-QOR, but not complex III, is inhibited by its bulky TPP + moiety. To explain its lack of reactivity with complex III we show that the TPP + moiety of MitoQ 10 is ineffective at quenching pyrene fluorophors deeply buried within phospholipid bilayers and thus is positioned near the membrane surface. This superficial position of the TPP + moiety, as well as the low solubility of MitoQ 10 in non-polar organic solvents, suggests that the concentration of the entire MitoQ 10 molecule in the membrane core is very limited. As overlaying MitoQ 10 onto the structure of complex III indicates that MitoQ 10 cannot react with complex III without its TPP + moiety entering the low dielectric of the membrane core, we conclude that the TPP + moiety does anchor the tethered ubiquinol group out of reach of the active site(s) of complex III and this explains its slow oxidation. In contrast the ubiquinone moiety of MitoQ 10 is able to quench fluorophors deep within the membrane core, indicating a high concentration of the ubiquinone moiety within the membrane and explaining its good antioxidant efficacy. These findings significantly improve our u n d e r s t a n d i n g o f T P P + -conjugated antioxidants and will facilitate the rational design of future mitochondria-targeted molecules.
MitoQ 10 is a ubiquinone that accumulates within mitochondria driven by a conjugated lipophilic triphenylphosphonium cation (TPP + ). Once there MitoQ 10 is reduced to its active ubiquinol form and this has been used to prevent mitochondrial oxidative damage and to infer the involvement of reactive oxygen species in signalling pathways. Here we show MitoQ 10 is effectively reduced by complex II, but is a poor substrate for complex I, complex III and electrontransferring flavoprotein (ETF):quinone oxidoreductase (ETF-QOR). This differential reactivity could be explained if the bulky TPP + moiety sterically hindered access of the ubiquinone group to enzyme active sites with a long, narrow access channel. Using a combination of molecular modelling and an uncharged analog of MitoQ 10 with a sterically similar triphenylcarbon moiety (tritylQ 10 ), we infer that the interaction of MitoQ 10 with complex I and ETF-QOR, but not complex III, is inhibited by its bulky TPP + moiety. To explain its lack of reactivity with complex III we show that the TPP + moiety of MitoQ 10 is ineffective at quenching pyrene fluorophors deeply buried within phospholipid bilayers and thus is positioned near the membrane surface. This superficial position of the TPP + moiety, as well as the low solubility of MitoQ 10 in non-polar organic solvents, suggests that the concentration of the entire MitoQ 10 molecule in the membrane core is very limited. As overlaying MitoQ 10 onto the structure of complex III indicates that MitoQ 10 cannot react with complex III without its TPP + moiety entering the low dielectric of the membrane core, we conclude that the TPP + moiety does anchor the tethered ubiquinol group out of reach of the active site(s) of complex III and this explains its slow oxidation. In contrast the ubiquinone moiety of MitoQ 10 is able to quench fluorophors deep within the membrane core, indicating a high concentration of the ubiquinone moiety within the membrane and explaining its good antioxidant efficacy. These findings significantly improve our u n d e r s t a n d i n g o f T P P + -conjugated antioxidants and will facilitate the rational design of future mitochondria-targeted molecules.
The mitochondria-targeted antioxidant MitoQ 10 comprises a triphenylphosphonium cation (TPP   +   ) 1 attached to a ubiquinone moiety by a saturated 10-carbon chain (1) . The lipophilic cation leads to the extensive accumulation of MitoQ 10 within mitochondria where the ubiquinone is reduced to its active antioxidant ubiquinol form (1) (2) (3) . Accumulation and subsequent reduction of MitoQ 10 leads to protection against mitochondrial oxidative damage in a number of in vitro and in vivo systems (4-7). As MitoQ 10 is thought to act primarily in the membrane phase by preventing lipid peroxidation (1-3), we attempted to optimize its efficacy by varying the length of the alkyl chain linking the TPP + and ubiquinone moieties (MitoQ n , n = 3, 5, 10 and 15). With these analogs we observed a positive correlation between alkyl chain length and antioxidant efficacy (2) and between alkyl chain length and reduction to its antioxidant ubiquinol form by complex II (3) . Furthermore, some oxidoreductases failed to react with any of the MitoQ analogs at an appreciable level (3) . To infer the principal sites of reduction of MitoQ 10 to its antioxidant form within mitochondria, we measured the activity of MitoQ 10 with isolated complex I, complex II and electron-transferring flavoprotein (ETF):quinone oxidoreductase (ETF-QOR). Here we show that MitoQ 10 is rapidly reduced by isolated complex II, but is not a good substrate for isolated ETF-QOR or complex I.
While the greater hydrophobicity of the longer MitoQ analogs would have increased their partitioning into the lipid phase where they would be most available for reduction by dehydrogenases and protective against lipid peroxidation (2,3), differences in how MitoQ reacted with individual ubiquinone oxidoreductases suggested two additional factors arising from the size and the charge of its TPP + moiety (3) . The TPP + group of MitoQ is somewhat bulkier than the ubiquinone moiety raising the possibility of sterically hindered access to the active sites of some mitochondrial ubiquinone oxidoreductases. Using a sterically similar analog of MitoQ 10 in which the positively-charged phosphonium is replaced with a neutral carbon (tritylQ 10 ; Fig. 1A ), we show that bulkiness of the TPP + moiety is likely to diminish MitoQ 10 reduction by complex I.
However, bulkiness does not contribute to the poor oxidation of the reduced form of MitoQ 10 by complex III. We believed this could be explained by the complicated interaction of relatively hydrophilic TPP + -derivatives, such as the methyltriphenylphosphonium cation (TPMP + ), with phospholipid bilayers (8) . Numerous studies have led to the following model for the passage of such lipophilic cations through membranes (9-13). The cations initially adsorb to the membrane as a monolayer in a potential energy well at the level of the fatty acid carboxyl groups. The cations then pass through the hydrophobic core of the membrane to the potential energy well on the other side of the membrane before desorbing into the aqueous phase. This model suggests that the steady-state cation concentration in the membrane core is relatively low and that their location is tightly constrained close to the membrane surfaces. However, it was not clear whether this model holds for TPP + conjugated to a very hydrophobic component, as is the case for MitoQ 10 . Therefore, it remained uncertain whether MitoQ- 10 was dissolved in the membrane core to a significant extent, or whether its TPP + component was constrained to a position near the membrane surface with the ubiquinone penetrating to a depth determined by the length of the alkyl linker. To address this issue, it was essential to understand better the position and orientation of MitoQ 10 bound to membranes. For this we studied the interaction of MitoQ 10 with phospholipid bilayers through collisional quenching of a series of fluorescent pyrene probes (14) . The data obtained are consistent with a model in which the TPP + moiety is largely excluded from the hydrophobic core, while the ubiquinone is inserted into it. Thus the restricted orientation of MitoQ 10 is likely to explain the decreased reactivity of it with complex III.
Our findings have significant implications for understanding of the interaction of MitoQ 10 and other mitochondria-targeted compounds with mitochondrial membranes and enzymes. 10 and MitoQ 15 were synthesized as described previously (1) (2). TritylQ 10 was prepared from idebenol as outlined in on-line Supplementary Figure 1 . Other ubiquinone analogs were sourced as described previously (15) . The structures of some of these are shown in Fig. 1A .
MATERIALS AND METHODS

Materials
Fluorescence quenching -To prepare small unilamellar vesicles (SUV), 4.8 µL of 10 mM 1-pyrene carboxylic acid in DMSO and 480 µL of either 25 mg.mL -1 turkey egg yolk L-α -phosphatidyl choline (PC; ~60% PC, Type XII-E, Sigma) or 25 mg.mL -1 soybean asolectin (~55% PC, Type IV-S, Sigma) in chloroform were evaporated to dryness under a stream of nitrogen in a 15 mL glass Kimax tube. Residual chloroform was removed under vacuum before 12 mL of KP i buffer (50 mM KP i -KOH (pH 7.8), 100 µM EDTA and 100 µM diethylenetriaminepentaacetic acid) was added followed by incubation for 1 hr at room temperature. The tube was then vortexed vigorously and placed in a Decon F5 Minor sonicating water bath for 30 min at room temperature. To assess the size distribution of the egg yolk SUV preparation 2 µL was adsorbed to a Cu/Rh grid for 2 min before blotting. Uranyl acetate (1%) was immediately applied for 8 s before thorough blotting. The grids were visualised using a Tecnai 12 electron by guest on September 1, 2017 http://www.jbc.org/ Downloaded from microscope at 26,000 x magnification. The SUVs had a mean external spherical diameter of 86 nm with a standard deviation of 26 nm (n = 35).
Pyrene quenching was assayed in 2.5 mL of the SUV suspension (1 mg.mL -1 ) in a stirred cuvette with a Shimadzu RF 5301-PC fluorimeter (λ ex 343-346 ± 1.5 nm, λ em 377 ± 0.75 nm) at 30˚C. Five 2 µL additions from 10 mM stock solutions of MitoQ 10 , decylQ, idebenone or decylTPP in ethanol were made at 30-60 s intervals and the fluorescence measured before (I 0 ) and after (I) each addition. Fluorescence quenching was plotted as I 0 /I-1 vs. the concentration (mM) of MitoQ 10 , decylQ, idebenone or decylTPP, with the slope of the line being the Stern-Volmer (SV) constant (14) . The loss of Pyr 2 fluorescence upon ubiquinone addition in bulk phase ethanol was assumed to result from an inner filter effect, and the values for I 0 and I were corrected accordingly. Correction for the inner filter effect decreased the SV constants in SUVs and mitochondrial membranes when a ubiquinone was the quencher by ~1 mM -1 . Experiments with decylTPP showed there was no inner filter effect due to the TPP + moiety. Bovine heart mitochondria were isolated, and mitochondrial membranes were prepared from these as described previously (16, 17) . For fluorescence quenching of 1-pyrene carboxylic acids, bovine heart mitochondrial membranes (800 µg protein.mL -1 ) were added to a stirred cuvette containing 2.5 mL KP i buffer in a Shimadzu RF 5301-PC fluorimeter (λ ex 343-346 ± 1.5 nm, λ em 377 ± 0.75 nm) at 37˚C. To this was added 1 µL of 10 mM 1-pyrene carboxylic acid in DMSO and once the fluorescence had stabilized, fluorescence quenching was determined as above. Binding of 1-pyrene carboxylic acids to bovine heart mitochondrial membranes (800 µg protein) was measured by incubating them in 1 mL KP i buffer containing 20 µM 1-pyrene carboxylic acid for 10 min at 37˚C. Membranes were pelleted by centrifugation (30 min at 16000 x g, 37˚C), after which the supernatant was removed and extracted 1-3 times with 1 mL octan-1-ol. The fraction of pyrene carboxylic acid in the aqueous phase was determined by measuring the A 345 of the combined octan-1-ol extracts and comparing it to the A 345 of the original 1-pyrene carboxylic acid solution in octan-1-ol. The concentration of Pyr 16 in the aqueous phase was too low to be measured accurately and thus all Pyr 16 was assumed to be membrane associated.
Solvent solubility -Serial dilutions of a 100 mM ethanol stock of the relevant ubiquinone were evaporated to dryness under vacuum in a 1.5 mL eppendorf tube. The ubiquinone (3-1000 nmol) was then resuspended in 1 mL of octan-1-ol or cyclohexane with vigorous vortexing. As MitoQ 10 was minimally soluble in cyclohexane and formed a separate orange phase, attempts were made to solubilize it further by placing it for 3 h in a shaking water bath at 37˚C or for 30 min in a Decon F5 Minor sonicating water bath. MitoQ 10 was solubilized to the same extent in cyclohexane after either treatment. After centrifugation (30 s at 13000 x g) the A 275 of the supernatant was measured to calculate the ubiquinone concentration.
Protein purification -Porcine ETF-QOR was purified from porcine liver submitochondrial particles as described previously (18) . Human ETF and human medium-chain acyl-CoA dehydrogenase (MCAD) were expressed from pET vectors in Escherichia coli and purified (19, 20) . Complex I was purified from bovine heart mitochondria (21) . Complex II was partially purified from bovine heart mitochondria. Briefly, mitochondria were solubilized in 20 mM Tris-HCl (pH 8), 1% (w/v) dodecylmaltoside, 500 µM EDTA. After centrifugation the supernatant was applied to a Q-Sepharose column in 20 mM Tris-HCl (pH 8), 0.1% (w/v) dodecylmaltoside, 50 mM sucrose, 2 mM MgSO 4 , 1 mM EDTA, 10% (v/v) glycerol. Protein was eluted using a linear gradient of 0-500 mM NaCl with complex II eluting at ~200 mM NaCl. Fractions containing complex II activity were pooled and concentrated using a 100 kDa cut off spin column (Vivascience) then applied to a 1.6 x 60 cm S-300 column equilibrated with 20 mM Tris-HCl (pH 8), 0.1% (w/v) dodecylmaltoside, 50 mM sucrose, 2 mM MgSO 4 , 1 mM EDTA, 10% (v/v) glycerol, 200 mM NaCl. Fractions containing complex II were pooled and concentrated using a 100 kDa cut off spin column.
Isolated enzyme assays -ETF-QOR was assayed in a reaction mixture containing 10 mM Hepes-KOH (pH 7. ).
Enzyme assays in bovine heart mitochondrial membranes -Although tritylQ 10 is soluble in octan-1-ol and cyclohexane up to 1 mM (data not shown), it is significantly more hydrophobic than MitoQ 10 . Direct addition to lipid containing buffer results in slow or uneven incorporation into bilayers as judged by fluorescence quenching of Pyr 12 (data not shown). As this effect was also observed with CoQ 4 it was used as a control. Incorporation of tritylQ 10 or CoQ 4 into phospholipids could be achieved by either sonication or reconstitution from chloroform. However, as conditions could not be easily achieved where either CoQ 4 or tritylQ 10 were substrates for isolated complex I or complex II, we used bovine heart mitochondrial membranes sonicated in the presence of tritylQ 10 or CoQ 4 .
Ubiquinone reduction by NADH in bovine heart mitochondrial membranes (100 µg.mL -1 ) was assayed in 20 mM Hepes-KOH (pH 7.5), 50 µM NAD + , 5 mM lactate, 200 µM KCN and 50 µM of either CoQ 4 , tritylQ 10 , decylQ or MitoQ 10 at 32˚C. After microtip sonication (Misonix 3000; 6 x 5s, 0˚C) in a glass vial the reaction mix was transferred to a stirred cuvette. Following preincubation, the reaction was initiated by addition of lactate dehydrogenase (5 U.mL -1 ) and monitored by measuring the decrease in A 275 . No decrease in A 275 occurred in the absence of ubiquinone or presence of 8 µg.mL -1 rotenone. Ubiquinone reduction by succinate in bovine heart mitochondrial membranes (100 µg.mL Ubiquinol oxidation by bovine heart mitochondrial membranes (50 µg.mL ). The increase in A 550 in the presence of 400 nM myxothiazol was subtracted. Ubiquinone was reduced by NaBH 4 , extracted and stored in ethanol (pH 2) as described previously (3). 10 to function as a recyclable antioxidant, effective reduction to its ubiquinol form within mitochondria is essential. We had previously observed poor reduction of MitoQ 10 by complex I in bovine heart mitochondrial membranes (3). However, these membranes contain endogenous CoQ 10 and several enzyme active sites that could catalyze redox exchange between CoQ 10 and MitoQ 10 . Furthermore, we did not know whether electrons from ß-oxidation, via electron-transferring flavoprotein:quinone oxidoreductase (ETF-QOR) could reduce MitoQ 10 . To investigate the interaction of MitoQ 10 with the major sites of ubiquinone reduction we isolated complex I, complex II and ETF-QOR and assayed their ability to reduce MitoQ 10 .
RESULTS
MitoQ 10 is a good substrate for isolated complex II but a poor substrate for isolated ETF-QOR and complex I -In order for MitoQ
When isolated complex II (succinate dehydrogenase) was incubated with MitoQ 10 the rate of ubiquinone reduction was identical to that for idebenone and decylQ (Fig. 1B) . This confirms that MitoQ 10 is a good substrate for this enzyme and is consistent with previous observations in bovine heart mitochondrial membranes (3). Complex I (NADH:ubiquinone oxidoreductase) is the route by which electrons enter the CoQ pool from mitochondrial NADH. When we incubated MitoQ 10 or MitoQ 15 with isolated complex I in the presence of supplementary phospholipids no rotenonesensitive ubiquinol generation (Suppl. Fig. 2 ) or NADH oxidation (Fig. 1C) , was observed. These results contrast with those when decylQ was used as an electron acceptor (Fig. 1C & Suppl. Fig. 2 ) and demonstrate that MitoQ 10 and MitoQ 15 are not substrates for isolated complex I, consistent with previous observations in mitochondrial membranes (3) . During ß-oxidation ETF-QOR accepts electrons from the soluble protein ETF, and in turn donates these to the CoQ pool. When isolated ETF-QOR was incubated with MitoQ 10 or MitoQ 15 the rates of reduction to the ubiquinol form were slow (Fig.  1D ). As decylQ, idebenone and a range of other ubiquinone derivatives are readily reduced by ETF-QOR ( Fig. 1D ) (15), it is concluded that the TPP + moiety inhibits access of MitoQ 10 and MitoQ 15 to the ubiquinone reduction site in ETF-QOR.
In summary, MitoQ 10 is a good substrate for isolated complex II, but a poor substrate for isolated ETF-QOR and complex I. Therefore complex II appears primarily responsible for reducing MitoQ 10 in vivo. We note that while glycerol-3-phosphate dehydrogenase can reduce MitoQ 10 (3), its location on the outer surface of the mitochondrial inner membrane and low expression in many tissues may limit its importance in vivo.
The bulkiness of its TPP
+ moiety contributes to the poor reactivity of MitoQ 10 with complex I and ETF-QOR, but not complex III -Having determined the likely site of MitoQ 10 reduction within mitochondria, our aim was to understand why MitoQ 10 was not reduced by ETF-QOR or complex I (Fig. 1) , or oxidized by complex III (3). Three possible explanations exist for the poor reactivity of MitoQ 10 with ETF-QOR, complex I and complex III; either the ubiquinone binding site is in a hydrophobic environment to which the positive charge of the TPP + moiety prevents access, there is a long narrow access channel that the bulky TPP + moiety cannot enter or they are inhibited by MitoQ 10 . Recently the structure of ETF-QOR was determined and shown to have a long narrow ubiquinone binding channel (24) . Overlaying MitoQ 10 with the ubiquinone moiety and five isoprenoid units of CoQ 10 visible in the ETF-QOR structure clearly indicates that the TPP + moiety of MitoQ 10 prevents its ubiquinone group from reaching the ubiquinone binding site of ETF-QOR (data not shown). Thus, steric hindrance caused by the bulkiness of its TPP + moiety is sufficient to explain the lack of reactivity of MitoQ 10 with ETF-QOR. In contrast, molecular modelling of MitoQ 10 with complex III shows that the TPP + moiety does not sterically prevent access of the ubiquinone group to active sites within complex III (3), suggesting an alternative explanation (see below).
Unlike ETF-QOR and complex III, there is little structural information available about the ubiquinone binding site(s) of complex I (25) . To differentiate between the first two possibilities we synthesized a similar sized but uncharged analog of MitoQ 10 in which the positivelycharged phosphonium at the centre of the TPP + moiety is replaced by a neutral carbon (tritylQ 10 ; Fig. 1A ). In contrast to MitoQ 10 , tritylQ 10 is very lipophilic and will easily permeate into the hydrophobic core of the membrane. Therefore if tritylQ 10 is not a substrate for complex I, it would imply that the large size of its terminal TPP + moiety contributes to the lack of MitoQ 10 reduction by complex I. Reduction and oxidation of tritylQ 10 was compared with CoQ 4 as both required sonication for effective incorporation into membranes (see the Materials and Methods section). TritylQ 10 is a less effective substrate for complex I than CoQ 4 ( Fig. 2A) , suggesting that the steric effect is important in this case. This appears to be compounded by the charge of the TPP + moiety as MitoQ 10 is even less reactive than tritylQ 10 (Fig. 2A) . In contrast to complex I, both tritylQ 10 and CoQ 4 are good substrates for complexes II and III (Figs. 2B & 2C) consistent with the lack of steric hindrance previously indicated by molecular modelling of MitoQ 10 with these complexes (3). However, contrary to tritylQ 10 , the reduced form of MitoQ 10 is poorly oxidized by complex III, suggesting that steric hindrance does not prevent access of MitoQ 10 to the active sites of complex III. Instead it is the charge on MitoQ 10 that limits its reactivity, possibly by preventing a high concentration of MitoQ 10 in the membrane.
In summary, steric hindrance does not play a role in the low reactivity of MitoQ 10 with complex III, but certainly contributes to the slow reduction of MitoQ 10 by complex I and ETF-QOR.
Inhibition of complexes I and III is not responsible for their poor reactivity with
MitoQ 10 -One potential explanation for the poor reactivity of MitoQ 10 with complexes I and III is that high concentrations of lipophilic cations can inhibit mitochondrial function. Consistent with this in bovine heart mitochondrial membranes there is some evidence of inactivation of complexes I and III in the presence of 50 µM decylTPP (data not shown). To confirm that the lack of MitoQ 10 reactivity with complex I and III (Fig. 2) does not solely arise from inhibition or inactivation, we measured the rate of decylQ reactivity with these complexes in the presence of lower concentrations of both redox forms of MitoQ 10 or decylTPP. The rate of decylQ reduction by Complex I was not inhibited by either the reduced or the oxidized forms of MitoQ 10 , or by decylTPP (Suppl. Fig. 3A ). In contrast, MitoQ 10 is largely unreactive with complex I when compared with decylQ in the presence of an equivalent amount of lipophilic cation (Suppl. Fig. 3A) . Similarly the rate of decylQ oxidation by complex III was not inhibited by the presence of either the reduced or the oxidized forms of MitoQ 10 , or by decylTPP (Suppl. Fig. 3B ). Like complex III, MitoQ 10 is largely unreactive with complex III when compared with decylQ in the presence of an equivalent amount of lipophilic cation (Suppl. Fig. 3B ). While in both cases, there is some redox exchange between the two hydrophilic ubiquinones, decylQ and MitoQ 10 , it is clear that complexes I and III are still active in the presence of both redox forms of MitoQ 10 .
In summary, enzyme inhibition or inactivation does not explain the poor reactivity of MitoQ 10 10 in different regions of the phospholipid bilayer varies and hence to gauge its overall molecular orientation, we measured its ability to quench the fluorescence of a pyrene moiety separated from a carboxylic acid by a carbon chain of n-1 methylene groups (Pyr n , n = 2, 4, 6, 10, 12, 16). This probe was chosen because at neutral pH the depth of the fluorescent pyrene label within the membrane will depend on the length of the chain between it and the carboxylate (14, 26) . As a result, the chain length-dependence of pyrene fluorescence quenching gives an indication of the relative position of the quencher within a membrane, as illustrated in Fig. 3A . To determine the position of a quenching moiety within a membrane, we prepared small unilamellar vesicles (SUVs) from egg yolk phospholipids containing a range of these 1-pyrene carboxylic acids. We then measured fluorescence quenching of the incorporated pyrene moiety upon addition of increasing amounts of various quenching molecules, the structures of which are shown in Fig. 1A . The fluorescence before (I 0 ) and after (I) each addition of quencher was plotted versus the quencher concentration, the slope being the Stern-Volmer (SV) constant. That the plot of I 0 /I-1 versus quencher concentration is linear indicates that quenching of pyrene fluorescence by TPP + and ubiquinone in SUVs is collisional (Fig. 3B) (14) . MitoQ 10 strongly quenched Pyr 10- and Pyr 4 which will lie closer to the bilayer surface (Figs. 3C & 3D) . As MitoQ 10 is a composite of a ubiquinone group and a TPP + moiety (Fig. 1A) , both of which might quench pyrenes, we next compared the fluorescence quenching of MitoQ 10 with decylTPP and idebenone (Fig. 3C) . These compounds were chosen as they are structurally related to MitoQ 10 , but lack the ubiquinone or TPP + moieties respectively. To minimize discrepancies due to differences in quencher concentration in the lipid phase and/or quenching efficiency, and to facilitate comparison of the depth within the membrane of each quenching moiety, these data were replotted as a percentage of the SV constant of the pyrene carboxylic acid that quenched most strongly (Fig. 3D) . Like MitoQ 10 , the ubiquinone moiety of idebenone maximally quenches the deeper lying Pyr [10] [11] [12] [13] [14] [15] [16] with significantly less quenching of the shallower Pyr [2] [3] [4] [5] [6] (Figs. 3C &  3D) . In contrast, decylTPP exhibits maximal quenching with Pyr 4 and none at all with Pyr 10 -Pyr 16 (Figs. 3C & 3D) , suggesting that the TPP + moiety is concentrated nearer the surface and does not have access to the core of the phospholipid bilayer. While the quenching profiles of MitoQ 10 and idebenone are similar, close inspection indicates that there are subtle differences. Pyr 4 is quenched significantly more by MitoQ 10 than idebenone (P = 0.004) and a relative increase in quenching by MitoQ 10 over idebenone is also observed with Pyr 2 and Pyr 6 . In fact the difference between the quenching profiles of idebenone and MitoQ 10 is very similar to the profile for decylTPP (Fig. 3E) suggesting that quenching by the two moieties is additive. This implies that the TPP + moiety of MitoQ 10 , like that of decylTPP, is found nearer the phospholipid bilayer surface while the ubiquinone group is buried within the bilayer.
The position of the carboxyl carbon of pyrene carboxylic acids is expected to be similar to that of anthroloxy-labelled fatty acids where the ionized carboxyl carbon resides 18.6 Å from the bilayer midplane, with the protonated uncharged form lying slightly deeper at 16 Å (26) . This places the carboxyl carbon close to the depth of the ester carbonyl groups on the acyl chains of phospholipids (27) . At pH 7.8 pyrene carboxylic acids are largely ionized while at pH 5 they will be ~50% neutral and thus will on average lie deeper within the membrane. In contrast, the net charges on the TPP + and ubiquinone moieties are pH-independent.
Therefore lowering the pH to 5.0 should result in the pyrene moiety moving deeper into the membrane relative to the quenching groups. Consistent with this scenario, MitoQ 10 and idebenone were much more effective at quenching Pyr 2-6 at pH 5.0 than at pH 7.8 while decylTPP was largely ineffective at quenching any of the pyrenes at pH 5.0 (Fig. 3C) . Thus this experimental system gives an indication of the position of the TPP + and ubiquinone moieties within the phospholipid bilayer.
DecylTPP, idebenone and MitoQ 10 were used because they have similar hydrophobicities (logP = 3.7, 4.2, 3.4 respectively in octan-1-ol:PBS) (3) and thus, all should partition predominantly (> 90%) into SUVs under our conditions, assuming a phospholipid volume of 1 µL.mg -1 (28) . This is an important consideration as the observed quenching is a function of the concentrations of quencher and fluorophor actually in the lipid phase, and is thus dependent on their hydrophobicities. To demonstrate that the quenchers were predominantly in the lipid phase decylQ, a ubiquinone analog ~10-fold more hydrophobic than idebenone (logP = 5.5 in octan-1-ol:PBS) (3), was used and showed a similar quenching profile to both idebenone and MitoQ 10 (Fig. 3D) . Thus all the quenchers used were predominantly in the lipid phase and the results are not compromised by small differences in quencher hydrophobicity. However, differential quencher partitioning became problematic for MitoQ derivatives with shorter chain lengths. When we compared MitoQ 3 (logP = 0.5 in octan-1-ol:PBS) with propylTPP and a 3-carbon analog of the 10-carbon linked idebenone, the level of quenching was weak, indicating that most of the quencher was present in the aqueous phase, and that the results were susceptible to small differences in quencher hydrophobicity (data not shown). This caveat is also true for the shorter pyrene carboxylic acids, a proportion of which may not be in the lipid phase.
To evaluate and address this latter issue we changed to a mitochondrial membrane system where we could separate the lipid and aqueous phases and thus correct for the proportion of pyrene carboxylic acid in the aqueous phase. Additionally, while the above work demonstrates that the TPP + moiety of MitoQ 10 is excluded from the hydrophobic core of a phospholipid bilayer, this may not be physiologically relevant as mitochondrial membranes contain a high proportion of protein and have a different lipid composition. To test whether these factors would facilitate penetration of the TPP + moiety of MitoQ 10 into the hydrophobic core, and to correct for the proportion of pyrene carboxylic acid in the aqueous phase, we measured fluorescence quenching in membranes isolated from bovine heart mitochondria. When compared with egg yolk SUVs, experiments with decylTPP gave stronger fluorescence quenching of Pyr [6] [7] [8] [9] [10] [11] [12] in mitochondrial membranes (Fig. 4A) . While this suggests the TPP + moiety of decylTPP can assume a slightly deeper position within mitochondrial membranes, it was ineffective at quenching Pyr 16 , the deepest penetrating pyrene carboxylic acid. As heart mitochondrial membranes differ from egg yolk phospholipids in several potentially important ways, e.g. they contain large amounts of protein, a higher proportion of unsaturated fatty acids, cardiolipin and little cholesterol (29) , it is difficult to assign a single reason for this increased penetration. However, to partially address this issue we tested the penetration of decylTPP + into soybean asolectin, which also has a high degree of unsaturation, but is free of cholesterol and has a significant proportion of negatively-charged phospholipids. In asolectin there was a similar increase in quenching of Pyr [10] [11] [12] [13] [14] [15] [16] by decylTPP (Fig. 4A) , suggesting the increased penetration of decylTPP into mitochondrial membranes may result from different lipid composition. In contrast to decylTPP, fluorescence quenching in mitochondrial membranes by MitoQ 10 was largely unaffected by differences between egg yolk SUVs and mitochondrial membranes (Fig.  4A) .
To determine the proportion of each pyrene carboxylic acid that was membraneassociated, we measured the fraction of each pyrene carboxylic acid in the aqueous phase. The percentages of Pyr 2 , Pyr 4 , Pyr 6 , Pyr 10 and Pyr 12 in the aqueous phase were 76 ± 5, 39 ± 1, 7 ± 1, 3 and 2, respectively, while the percentage of Pyr 16 in the aqueous phase was negligible. When the data in Fig. 4A are corrected for the concentration of membrane-associated pyrene carboxylic acid, the true position of the TPP + moiety of decylTPP is evaluated as being closer to the membrane surface as indicated by enhanced quenching of Pyr 2 and Pyr 4 and the decreased relative quenching of Pyr [6] [7] [8] [9] [10] [11] [12] (Fig. 4B) . Correction for pyrene carboxylic acid binding to mitochondrial membranes confirms that the ubiquinone moieties of both MitoQ 10 and idebenone are inserted into the membrane as they maximally quench Pyr [10] [11] [12] [13] [14] [15] [16] . However, correction enhances the relative quenching of Pyr 2 and Pyr 4 (Fig. 4B) , indicating the steadystate concentration of their ubiquinone moieties close to the membrane surface is higher in reality.
In summary, penetration of the ubiquinone moiety of MitoQ 10 into the membrane core is similar to uncharged ubiquinones such as idebenone and decylQ. In contrast, the TPP + moiety of MitoQ 10 is largely excluded from the hydrophobic core of phospholipid bilayers. Thus MitoQ 10 is orientated with its TPP + moiety near the surface of the membrane and its ubiquinone moiety inserted into the hydrophobic core of the lipid bilayer.
The TPP + moiety of MitoQ 10 greatly limits its solubility in cyclohexane -
The quenching data indicate that the TPP + moiety of MitoQ 10 is predominantly localized to near the membrane surface while the ubiquinone moiety is present in the membrane core. That the ubiquinone moiety of MitoQ 10 can quench buried pyrenes as effectively as lipid soluble ubiquinones such as idebenone indicates that the concentration of the ubiquinone moiety of MitoQ 10 within the membrane core is high. However, a notable difference between idebenone and MitoQ 10 is that the TPP + moiety constrains the orientation of MitoQ 10 and the free movement of its attached ubiquinone moiety within the hydrophobic core. While this should not affect interactions between the ubiquinone moiety of MitoQ 10 and diffusible pyrenes or lipid radicals, access to a deeply buried ubiquinone binding site of a ubiquinone oxidoreductase might not be possible unless the TPP + moiety moves into the hydrophobic core of the membrane. In this case the concentration of the entire MitoQ 10 molecule in the hydrophobic core of the phospholipid lipid bilayer will become the important variable and for efficient reduction it would need to be of the order of the K m for CoQ 10 of mitochondrial ubiquinone oxidoreductases. To estimate the steady-state concentration of MitoQ 10 in the hydrophobic core of the membrane, we measured the solubility of MitoQ 10 in cyclohexane (relative dielectric constant (ε r ) = 2) a solvent mimicking the hydrocarbon tail region of phospholipids in bilayers (30) . MitoQ 10 was largely insoluble in cyclohexane with a maximum concentration of 1-2 µM in solution (Fig. 5) . In contrast, MitoQ 10 was very soluble in octan-1-ol (ε r = 10.3), a more polar solvent that can form hydrogen bonds and mimics the ester region below the phospholipid head groups in membranes (Fig. 5) . The insolubility of MitoQ 10 in cyclohexane was caused by the TPP + moiety as idebenone, a ubiquinone of similar structure that lacks the TPP + moiety, was freely soluble in both cyclohexane and octan-1-ol up to at least 1 mM (Fig. 5) .
The relative insolubility of MitoQ 10 in cyclohexane could simply reflect insolubility induced by the counter-ion, methanesulfonate (CH 3 SO 3 -), in cyclohexane. In vivo the dominant anion would be Cl -so to mimic this environment we incubated 300 nmol MitoQ 10 with 1 mL cyclohexane:100 µL PBS, however there was no increase in the solubility of MitoQ 10 in cyclohexane (data not shown). More hydrophobic anions may be available in vivo for ion-pair formation thereby facilitating the solubilization of MitoQ 10 in the membrane. However, it was found that an equimolar amount (300 nmol) of sodium tetraphenylborate (TPB -), a lipophilic anion that facilitates the membrane permeability of lipophilic cations (31, 32) , failed to solubilize MitoQ 10 in cyclohexane (data not shown). As a result we conclude that irrespective of the counter-ions available to it in vivo MitoQ 10 will have low solubility in the non-polar hydrocarbon environment of the membrane core.
In summary, although MitoQ 10 is very soluble in octan-1-ol and will thus easily access the periphery of the bilayer, the solubility of MitoQ 10 in cyclohexane is ~2 µM. This indicates that the steady-state concentration of the entire MitoQ 10 molecule within the hydrophobic core of the phospholipid bilayer is likely to be significantly lower than the membrane concentration of endogenous CoQ (1-10 mM) in mitochondria from a range of tissues and species (33, 34) . As estimates of the K m for CoQ 10 
DISCUSSION
Here we have shown that the TPP + moiety of MitoQ 10 resides largely on the membrane surface with its ubiquinone group buried within the hydrophobic core of the bilayer. This conclusion is based on the observations that decylQ and idebenone, but not decylTPP, can quench 1-pyrene carboxylic acids where the pyrene is deep within the membrane core (Figs. 3 & 4) , and that MitoQ 10 has a low solubility in cyclohexane, a solvent mimicking the hydrophobic core (Fig.  5) . Thus, although TPP + -conjugated compounds can pass readily through phospholipid bilayers, the steady-state concentration of the TPP + moiety within the membrane core is very low. Instead, the TPP + moiety is located near the membrane surface with the extent of penetration of the attached group into the membrane determined by the length of the chain linking them. This orientation of MitoQ 10 leads to similar concentrations of the ubiquinone moiety within the membrane as occurs with short chain ubiquinone analogs such as idebenone or decylQ (Fig. 3C ). This is significant for the antioxidant action of MitoQ 10 as it suggests that its active ubiquinol moiety would have free access to lipid radicals throughout the membrane core.
Even though incubation with MitoQ 10 led to similar concentrations of the ubiquinone moiety within the membrane as were found on incubation with short-chain ubiquinone analogs (Figs. 3 & 4) , their interactions with ubiquinone oxidoreductases were dramatically different (Figs. 1 & 2) . The concentration of the ubiquinone moiety, not the whole MitoQ 10 molecule, in the membrane will be the important determinant in the quenching reaction with 1-pyrene carboxylic acids as there is no requirement for the TPP + moiety to move into the hydrophobic core for an interaction between pyrene and ubiquinone to take place. In contrast, the ubiquinone binding sites of ubiquinone oxidoreductases are of a fixed depth and access from the direction of the membrane surface may be sterically hindered. If the TPP + moiety of MitoQ 10 had to move into a hydrophobic environment for its ubiquinone moiety to reach the active site, this would be thermodynamically unfavourable; in this case the concentration of the entire MitoQ 10 molecule, not its ubiquinone moiety, in the membrane core would become the relevant variable. As shown in Fig. 5 the concentration of the entire MitoQ 10 molecule in the membrane core is much lower than uncharged ubiquinones.
Reduction of MitoQ 10 to a ubiquinol by mitochondrial ubiquinone reductases is essential for its antioxidant function in vivo. Additionally, subsequent oxidation of MitoQ 10 by complex III by guest on September 1, 2017 http://www.jbc.org/ Downloaded from would be required for it to function as an effective electron carrier in oxidative phosphorylation. Here we show that the interaction of MitoQ 10 with mitochondrial ubiquinone oxidoreductases is significantly different from that of artificial short-chain ubiquinone analogs, such as decylQ or idebenone. These findings indicate that MitoQ 10 is not effectively reduced to its antioxidant form by complex I or ETF-QOR, and that the principal mitochondrial enzyme responsible for reducing MitoQ 10 to its ubiquinol form in vivo is complex II. This is supported by further measurements in heart mitochondrial membranes where the physiological ratios of respiratory complexes are conserved; the absolute rate of MitoQ 10 .mg protein -1 for glycerol-3-phosphate (3). This level of MitoQ 10 reduction by complex II is clearly sufficient for it to function as a highly effective antioxidant in preventing mitochondrial oxidative damage in vivo (1-3,5) . In contrast, MitoQ 10 is poorly oxidized by complex III suggesting it would be an ineffective replacement for CoQ 10 in oxidative phosphorylation.
Can the reactivity of MitoQ 10 be rationalized with what is known about the structures of the various mitochondrial ubiquinone oxidoreductases? Complex II is a transmembrane protein with a ubiquinone binding site near the matrix surface of the membrane (37) . The ubiquinone binding site of complex II is accessed via a short channel which the ubiquinone moiety of MitoQ 10 can access while the TPP + moiety remains on the membrane surface (3). Consistent with this, the rate of reduction of MitoQ 1 0 and short-chain ubiquinones by complex II was identical (Figs. 1  & 4) , indicating that all compounds could easily access its ubiquinone binding site. While the access channel is too short to sterically hinder MitoQ 10 , molecular modelling indicates steric hindrance of MitoQ 3 , and MitoQ 3 is a less effective substrate for complex II (3).
In contrast, MitoQ 10 is not oxidized by complex III (Fig. 2) and is not reduced by ETF-QOR or complex I, even though the other shortchain ubiquinone analogs were ( Fig. 1 & 2) . This occurs despite similar concentrations of the ubiquinone moieties of MitoQ 10 , idebenone and decylQ within the membrane (Fig. 3C) . One possible explanation for the lack of reactivity is that the ubiquinone binding sites of complex I, complex III and ETF-QOR have long, narrow access channels to which entry of MitoQ 10 is sterically hindered by its TPP + moiety. A second potential reason is that the ubiquinone binding site is not sterically hindered, but is buried within the hydrophobic core of the membrane where the concentration of MitoQ 10 is low. A further consideration for the latter explanation is that the long hydrophobic tail of CoQ 10 resides in the midplane of phospholipid bilayers (34) . Such a location for CoQ 10 requires that ubiquinone oxidoreductases have ubiquinonebinding sites that can be entered from the core of the membrane, often at the expense of access from the direction of the membrane surface. Entry of the ubiquinone moiety of MitoQ 10 to ubiquinone binding sites facing the midplane could thus be hindered as it would be thermodynamically unfavourable for MitoQ 10 to take on the required orientation, i.e. with its TPP + moiety in the hydrophobic core of the membrane.
ETF-QOR is a monotopic membrane protein with the molecular structure depicting five isoprenoids from CoQ 10 entering the ubiquinone reduction site from the lipid phase via a channel at the base of the enzyme (24) . When MitoQ 10 is modelled into this active site the bulky TPP + moiety sterically hinders access of the ubiquinone group and this would appear sufficient to prevent MitoQ 10 reacting with ETF-QOR (data not shown). However, as CoQ 10 enters from the direction of the bilayer midplane and the TPP + of MitoQ 10 would need to enter the lipid phase for its ubiquinone to reach the active site, both mechanisms could in principle contribute to the lack of reactivity of MitoQ 10 with ETF-QOR. There is no molecular structure for the ubiquinone binding site(s) of complex I (25). Here we showed that while tritylQ 10 can be reduced by complex I, this rate is slower than CoQ 4 , but faster than MitoQ 10 ( Fig. 2A) . This indicates that steric hindrance is a substantial component of the diminished reactivity of MitoQ 10 with complex I. This may be amplified by the low concentration of MitoQ 10 in the membrane core. Complex III contains both a ubiquinone reduction site and a ubiquinol oxidation site, each of which is nearer to and accessed from the direction of the bilayer midplane. The structure of complex III indicates that MitoQ 10 can enter both ubiquinone binding sites of complex III without steric hindrance (3, 38) . Here we confirm this by showing that a neutral, sterically similar version of MitoQ 10 , tritylQ 10 , can be oxidized by complex III (Fig.  2C) . As steric hindrance is not a factor and the ubiquinone binding sites of complex III are buried within the hydrophobic core, we conclude that MitoQ 10 is weakly oxidized by complex III primarily because the positive charge of the TPP + tethers the ubiquinone group to the membrane surface.
That the effective interaction of MitoQ 10 with enzyme active sites could be limited by tethering of its ubiquinone group to a TPP + moiety constrained to near the membrane surface, is further supported by the low µM steady-state concentration of the entire MitoQ 10 molecule in a solvent mimicking the bilayer core (Fig. 5) . This concentration is far lower than that of CoQ 10 in mitochondrial membranes (~5 mM) (33, 34) . Furthermore, estimates of the K m for endogenous CoQ 10 for NADH, succinate and glycerol-3-phosphate oxidation in the lipid phase are 5 mM, 500 µM, and 700 µM (34-36) with the K m of complex I for artificial decylQ higher still (~140 mM) (34) . Therefore, the lack of oxidation of MitoQ 10 by complex III (Fig. 2) is consistent with the TPP + moiety inhibiting penetration of the ubiquinone group into the hydrophobic environment surrounding the ubiquinone-binding sites of this enzyme.
In summary, here we have shown that the favoured orientation of MitoQ 10 is with the TPP + moiety near the membrane surface and the ubiquinone penetrating into the membrane core (Figs. 3 & 4) . This orientation enables the ubiquinone moiety to access the membrane core to act as a chain breaking antioxidant and allows recycling of MitoQ 10 to its ubiquinol form via reduction by complex II. In contrast MitoQ 10 cannot be oxidized by complex III explaining why it does not function as an electron carrier in mitochondrial respiration (3) . These findings have significant implications for our understanding of the mode of action of mitochondria-targeted ubiquinones and will allow the rational optimization of other mitochondria-targeted molecules. 1 The abbreviations used are: BHM, bovine heart mitochondrial membranes; CHAPS, 3-[(3-cholamidoproyl) dimethylammonio]-1-propane-sulfonate; CoQ 1-10 , ubiquinone with a tail of 1-10 isoprenoid units (2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinone); cyt c, cytochrome c; ETF, electron-transferring flavoprotein; ETF-QOR, electron-transferring flavoprotein:quinone oxidoreductase; MCAD, medium-chain acyl-CoA dehydrogenase; MitoQ, ubiquinone linked to a triphenylphosphonium cation by an alkyl chain of unspecified length; MitoQ n , ubiquinone linked to a triphenylphosphonium cation by an alkyl chain of n methylene groups; PC, phosphatidylcholine; Pyr n , pyrene linked to a carboxylic acid by an alkyl chain of n-1 methylene groups; SUV, small unilamellar vesicle; SV, Stern-Volmer constant; TPB -, tetraphenylborate anion; TPMP, methyltriphenylphosphonium cation; TPP + , triphenylphosphonium cation; ε r , relative dielectric constant. ) was added to buffer containing 5 mM succinate, asolectin, CHAPS and 50 µM of either decylQ, idebenone or MitoQ 10 . The reaction was monitored as the decrease in absorbance at 275 nm due to ubiquinone reduction and this was completely inhibited by 20 mM malonate. Data are the means ± SD of 3 independent experiments. C, isolated complex I in the presence of MitoQ 10 15 . The reaction was monitored as the decrease in absorbance at 275 nm due to ubiquinone reduction. Data are the means ± SD. Fig. 2 . TritylQ 10 , an uncharged, but sterically similar MitoQ 10 analog, shows that steric hindrance contributes to the poor reactivity of MitoQ 10 with complex I. A, MitoQ 10 and tritylQ 10 are both poorly reduced by complex I. Rotenone-sensitive ubiquinone reduction by NADH in bovine heart mitochondrial membranes (100 µg.mL ) was assayed in buffer with 50 µM of either CoQ 4 , tritylQ 10 , decylQ or MitoQ 10 . The reaction was initiated by addition of 5 mM succinate and monitored by measuring the decrease in A 275 . The rate in the presence of 20 mM malonate was negligible, but still subtracted. Data are the means ± SEM of 3 experiments. C, tritylQ 10 , but not MitoQ 10 , is oxidized by complex III. Myxothiazol-sensitive ubiquinol oxidation by bovine heart mitochondrial membranes (50 µg.mL ( A ), MitoQ 10 ( G ) and decylQ ( H ) maximally quench 1-pyrene carboxylic acids at pH 7.8. E, the difference between MitoQ 10 and idebenone quenching ( G ) at pH 7.8 mimics quenching by decylTPP ( B ). All data are mean ± SEM of three independent experiments. The statistical significance of pyrene quenching by MitoQ 10 relative to idebenone was determined using a Student's two-tailed ttest: * P < 0.01. Ubiquinone Added (nmol) [Ubiquinone] in Solution (µM)
